Advertisement
New Zealand markets closed
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NZD/USD

    0.6144
    -0.0027 (-0.43%)
     
  • NZD/EUR

    0.5733
    -0.0008 (-0.14%)
     
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • OIL

    78.49
    -0.13 (-0.17%)
     
  • GOLD

    2,348.40
    +30.40 (+1.31%)
     
  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • NZD/JPY

    96.6520
    -0.1680 (-0.17%)
     

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif., May 22, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.

  • William Blair 44th Annual Growth Stock Conference in Chicago
    Presentation on Tuesday, June 4 at 3:20 p.m. CT / 4:20 p.m. ET

  • Jefferies Global Healthcare Conference in New York
    Presentation on Wednesday, June 5 at 5:00 p.m. ET / 2:00 p.m. PT

  • Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida
    Fireside chat on Tuesday, June 11 at 2:00 p.m. ET / 11:00 a.m. PT

Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

ADVERTISEMENT

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522599294/en/

Contacts

Investor Contact:
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711